Is Mobotinib effective in the treatment of lung cancer?

Mobosetinib (mobosetinib) has a remarkable effect in the treatment of lung cancer, especially for patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. Here's a detailed analysis of its effectiveness:

1.Highly targeted: Mobotinib is a drug designed specifically for EGFR 20 exon insertion mutations. This mutation is the third most common mutation in EGFR targets, but due to its special spatial structure and similar characteristics to traditional EGFR, drug development is difficult. The emergence of Mobotinib has just filled this treatment gap.

2.Clinical data support: According to clinical research data, mobotinib has shown significant efficacy in the treatment of NSCLC patients with EGFR exon 20 insertion mutations. In patients whose disease progressed during or after platinum-based chemotherapy, median progression-free survival (mPFS) improved to 7.3 with mobotinib. months, and the median overall survival (mOS) was extended to 20.2 months. This data is significantly better than traditional chemotherapy regimens, showing the significant effect of mobotinib in prolonging patient survival.

3.Breakthrough treatment options: Before the emergence of mobotinib, lung cancer patients with EGFR exon 20 insertion mutations mainly relied on chemotherapy, but the effect was limited. Mobotinib not only breaks this treatment dilemma, but also provides patients with new treatment options, making targeted targeted therapy possible.

4.Improve patient prognosis: EGFR 20Exon insertion mutation late stageNSCLCThe survival prognosis of patients is usually poor. In the absence of effective treatment, the objective response rate of second-line and later-line treatments is less than 10%, PFS is only 3.7 months, OS is only 13.6 months. The emergence of mobotinib is expected to significantly improve the prognosis of these patients.